KYTHERA Biopharmaceuticals Announces Closing of Public Offering and Exercise of Underwriters' Over-Allotment Option
March 16, 2015 16:05 ET
|
KYTHERA Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., March 16, 2015 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced the closing of its underwritten public offering of 2,994,793 shares of its...
KYTHERA Biopharmaceuticals Announces Pricing of Public Offering of Common Stock
March 10, 2015 21:52 ET
|
KYTHERA Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., March 10, 2015 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced the pricing of its underwritten public offering of 2,604,168 shares of its...
KYTHERA Biopharmaceuticals Announces Proposed Public Offering of Common Stock
March 09, 2015 16:01 ET
|
KYTHERA Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., March 9, 2015 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced it has commenced an underwritten public offering of $125 million of shares of...
KYTHERA Biopharmaceuticals Announces FDA Advisory Committee Unanimously (17-0) Recommends to Approve ATX-101 (deoxycholic acid) Injection to Improve the Appearance of Moderate to Severe Submental Fullness
March 09, 2015 12:45 ET
|
KYTHERA Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., March 9, 2015 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) announced today that the U.S. Food and Drug Administration's (FDA) Dermatologic and...
KYTHERA Biopharmaceuticals Grants Stock Options Under Inducement Program
March 04, 2015 22:55 ET
|
KYTHERA Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., March 4, 2015 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that the Compensation Committee of the Company's Board of Directors granted...
KYTHERA Biopharmaceuticals Announces 2014 Operating Results
March 02, 2015 16:56 ET
|
KYTHERA Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., March 2, 2015 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today reported financial results for its quarter and year ended December 31, 2014, and...
KYTHERA Acquires Worldwide Rights to Clinical Compound and Key Intellectual Property for Potential Novel Treatment of Hair Loss
February 10, 2015 16:22 ET
|
KYTHERA Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., Feb. 10, 2015 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that it has entered into separate license agreements with Actelion...
KYTHERA Biopharmaceuticals to Present at the 2015 Leerink Global Healthcare Conference
February 04, 2015 19:00 ET
|
KYTHERA Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., Feb. 4, 2015 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that Keith Leonard, president and chief executive officer, will present at the...
KYTHERA Biopharmaceuticals Submits Drug Application in Australia for Novel Submental Contouring Injectable Drug ATX-101
February 04, 2015 16:22 ET
|
KYTHERA Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., Feb. 4, 2015 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced its submission to Australia's Therapeutic Goods Administration (TGA) for...
KYTHERA Biopharmaceuticals Grants Stock Options Under Inducement Program
February 03, 2015 20:25 ET
|
KYTHERA Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., Feb. 3, 2015 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that on January 30, 2015, the Compensation Committee of the Company's Board of...